Iovance

Nov 04, 2021

•

Sep 30, 2021

Iovance Q3 2021 Earnings Report

Reported third quarter and year-to-date financial results and corporate updates.

Key Takeaways

Iovance Biotherapeutics reported a net loss of $86.1 million, or $0.55 per share, for the third quarter ended September 30, 2021. The company had $660.8 million in cash, cash equivalents, investments and restricted cash at September 30, 2021. They are focused on addressing FDA feedback regarding potency assays for lifileucel to support their planned BLA submission.

Continued to report long-term clinical data demonstrating the durability of one-time treatment with lifileucel in metastatic melanoma.

Broadened the potential for TIL cell therapy to address more patients in additional indications and treatment settings.

Top priority remains ongoing work to address FDA feedback regarding potency assays for lifileucel to support planned BLA submission.

The company had $660.8 million in cash, cash equivalents, investments and restricted cash at September 30, 2021.